Recommendations of the French Society for Rheumatology for managing rheumatoid arthritis

Joint Bone Spine

Volumn 81, Issue 4, 2014, Pages 287-297

  Gaujoux Viala, Cécile ^a   Gossec, Laure ^b   Cantagrel, Alain ^c   Dougados, Maxime ^d   Fautrel, Bruno ^b   Mariette, Xavier ^e   Nataf, Henri ^f   Saraux, Alain ^g,h   Trope, Sonia ⁱ   Combe, Bernard ^j  

^a NÎMES UNIVERSITY HOSPITAL   (France)

^b SORBONNE UNIVERSITÉ   (France)

^c TOULOUSE UNIVERSITY HOSPITAL   (France)

^d UNIVERSITÉ PARIS DESCARTES   (France)

^e INSERM   (France)

^f Cabinet de rhumatologie   (France)

^g SERVICE DE RHUMATOLOGIE   (France)

^h Universite de Brest   (France)

ⁱ ANDAR Association Nationale de Défense contre l'Arthrite Rhumatoïde   (France)

^j LAPEYRONIE HOSPITAL   (France)

more..

Author keywords

Biologics; Glucocorticoid therapy; Recommendations; Rheumatoid arthritis; Treatment

Indexed keywords

DISEASE MODIFYING ANTIRHEUMATIC DRUG; GLUCOCORTICOID; LEFLUNOMIDE; METHOTREXATE; SALAZOSULFAPYRIDINE; ABATACEPT; BIOLOGICAL PRODUCT; C REACTIVE PROTEIN; CYCLIC CITRULLINATED PEPTIDE ANTIBODY; RHEUMATOID FACTOR; RITUXIMAB; TUMOR NECROSIS FACTOR ALPHA INHIBITOR;

ARTICLE; DISEASE ACTIVITY; FOLLOW UP; GENERAL PRACTITIONER; HUMAN; META ANALYSIS (TOPIC); MONOTHERAPY; PATIENT CARE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REMISSION; RHEUMATOID ARTHRITIS; RHEUMATOLOGY; SELF HELP; SHORT COURSE THERAPY; ALGORITHM; BONE EROSION; CLINICAL DISEASE ACTIVITY INDEX; COMORBIDITY; DAS28; DISEASE CONTROL; DOCTOR PATIENT RELATION; DOPPLER ECHOGRAPHY; DRUG CONTRAINDICATION; DRUG HYPERSENSITIVITY; DRUG TREATMENT FAILURE; ERYTHROCYTE SEDIMENTATION RATE; FOREFOOT SQUEEZE TEST; HAND RADIOGRAPHY; HAND SQUEEZE TEST; HEALTH CARE COST; JOINT; JOINT SWELLING; METACARPOPHALANGEAL JOINT; METATARSOPHALANGEAL JOINT; MORNING STIFFNESS; MUSCULOSKELETAL SYSTEM EXAMINATION; OPTIMAL DRUG DOSE; PATIENT EDUCATION; PATIENT REFERRAL; PROXIMAL INTERPHALANGEAL JOINT; RISK BENEFIT ANALYSIS; SIMPLIFIED DISEASE ACTIVITY INDEX; SYNOVITIS; THORAX RADIOGRAPHY; TREATMENT RESPONSE; VISUAL ANALOG SCALE;

BIOLOGICS; GLUCOCORTICOID THERAPY; RECOMMENDATIONS; RHEUMATOID ARTHRITIS; TREATMENT;

ARTHRITIS, RHEUMATOID; HUMANS;

EID: 84904090047     PISSN: 1297319X     EISSN: 17787254     Source Type: Journal    
DOI: 10.1016/j.jbspin.2014.05.002     Document Type: Article

References (122)

1. Guillemin F., Saraux A., Guggenbuhl P., et al. Prevalence of rheumatoid arthritis in France: 2001. Ann Rheum Dis 2005, 64:1427-1430.
2. Minaur N.J., Jacoby R.K., Cosh J.A., et al. Outcome after 40years with rheumatoid arthritis: a prospective study of function, disease activity, and mortality. J Rheumatol Suppl 2004, 69:3-8.
3. Callahan L.F., Pincus T. Mortality in the rheumatic diseases. Arthritis Care Res 1995, 8:229-241.
4. Kvalvik A.G., Jones M.A., Symmons D.P. Mortality in a cohort of Norwegian patients with rheumatoid arthritis followed from 1977 to 1992. Scand J Rheumatol 2000, 29:29-37.
5. Dadoun S., Zeboulon-Ktorza N., Combescure C., et al. Mortality in rheumatoid arthritis over the last fifty years: systematic review and meta-analysis. Joint Bone Spine 2013, 80:29-33.
6. o22) de la HAS. http://www.has-sante.fr/.
7. Smolen J.S., Landewé R., Breedveld F.C., et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update. Ann Rheum Dis 2014, 73:492-509.
8. Gaujoux-Viala C., Nam J., Ramiro S., et al. Efficacy of conventional synthetic disease-modifying antirheumatic drugs, glucocorticoids and tofacitinib: a systematic literature review informing the 2013 update of the EULAR recommendations for management of rheumatoid arthritis. Ann Rheum Dis 2014, 73:510-515.
9. Nam J.L., Ramiro S., Gaujoux-Viala C., et al. Efficacy of biological disease-modifying antirheumatic drugs: a systematic literature review informing the 2013 update of the EULAR recommendations for the management of rheumatoid arthritis. Ann Rheum Dis 2014, 73:516-528.
10. Ramiro S., Gaujoux-Viala C., Nam J.L., et al. Safety of synthetic and biological DMARDs: a systematic literature review informing the 2013 update of the EULAR recommendations for management of rheumatoid arthritis. Ann Rheum Dis 2014, 73:529-535.
11. OCEBM Levels of Evidence Working Group The Oxford 2011 Levels of Evidence 2011, Vol. Oxford Centre for Evidence-Based Medicine.
12. Emery P., Breedveld F.C., Dougados M., et al. Early referral recommendation for newly diagnosed rheumatoid arthritis: evidence-based development of a clinical guide. Ann Rheum Dis 2002, 61:290-297.
13. Dougados M., Soubrier M., Antunez A., et al. Prevalence of comorbidities in rheumatoid arthritis and evaluation of their monitoring: results of an international, cross-sectional study (COMORA). Ann Rheum Dis 2014, 73:62-68.
14. Osiri M., Sattayasomboon Y. Prevalence and outpatient medical costs of comorbid conditions in patients with rheumatoid arthritis. Joint Bone Spine 2013, 80:608-612.
15. Kobelt G., Woronoff A.S., Richard B., et al. Disease status, costs and quality of life of patients with rheumatoid arthritis in France: the ECO-PR Study. Joint Bone Spine 2008, 75:408-415.
16. Fautrel B., Verstappen S.M.M., Boonen A. Economic consequences and potential benefits. Best Pract Res Clin Rheumatol 2011, 25:607-624.
17. Fries J.F., Spitz P., Kraines R.G., et al. Measurement of patient outcome in arthritis. Arthritis Rheum 1980, 23:137-145.
18. Olofsson T., Englund M., Saxne T., et al. Decrease in sick leave among patients with rheumatoid arthritis in the first 12 months after start of treatment with tumour necrosis factor antagonists: a population-based controlled cohort study. Ann Rheum Dis 2010, 69:2131-2136.
19. Lukas C., Combe B., Ravaud P., et al. Favorable effect of very early disease-modifying antirheumatic drug treatment on radiographic progression in early inflammatory arthritis: data from the Étude et suivi des polyarthrites indifférenciées récentes (Study and follow-up of early undifferentiated polyarthritis). Arthritis Rheum 2011, 63:1804-1811.
20. Visser H., le Cessie S., Vos K., et al. How to diagnose rheumatoid arthritis early: a prediction model for persistent (erosive) arthritis. Arthritis Rheum 2002, 46:357-365.
21. Aletaha D., Neogi T., Silman A.J., et al. 2010 rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Ann Rheum Dis 2010, 69:1580-1588.
22. Van der Heijde D., van der Helm-van Mil A.H.M., Aletaha D., et al. EULAR definition of erosive disease in light of the 2010 ACR/EULAR rheumatoid arthritis classification criteria. Ann Rheum Dis 2013, 72:479-481.
23. Colebatch A.N., Edwards C.J., Østergaard M., et al. EULAR recommendations for the use of imaging of the joints in the clinical management of rheumatoid arthritis. Ann Rheum Dis 2013, 72:804-814.
24. Munro R., Hampson R., McEntegart A., et al. Improved functional outcome in patients with early rheumatoid arthritis treated with intramuscular gold: results of a five-year prospective study. Ann Rheum Dis 1998, 57:88-93.
25. Van der Heide A., Jacobs J.W., Bijlsma J.W., et al. The effectiveness of early treatment with "second-line" antirheumatic drugs. A randomized, controlled trial. Ann Intern Med 1996, 124:699-707.
26. Anderson J.J., Wells G., Verhoeven A.C., et al. Factors predicting response to treatment in rheumatoid arthritis: the importance of disease duration. Arthritis Rheum 2000, 43:22-29.
27. Nell V.P., Machold K.P., Eberl G., et al. Benefit of very early referral and very early therapy with disease-modifying antirheumatic drugs in patients with early rheumatoid arthritis. Rheumatology (Oxford) 2004, 43:906-914.
28. Van Aken J., Lard L.R., le Cessie S., et al. Radiological outcome after four years of early versus delayed treatment strategy in patients with recent-onset rheumatoid arthritis. Ann Rheum Dis 2004, 63:274-279.
29. Lard L.R., Visser H., Speyer I., et al. Early versus delayed treatment in patients with recent-onset rheumatoid arthritis: comparison of two cohorts who received different treatment strategies. Am J Med 2001, 111:446-451.
30. Combe B., Logeart I., Belkacemi M.C., et al. Comparison of the long-term outcome for patients with rheumatoid arthritis with persistent moderate disease activity or disease remission during the first year after diagnosis: data from the ESPOIR cohort. Ann Rheum Dis 2014, 10.1136/annrheumdis-2013-204178.
31. Listing J., Kekow J., Manger B., et al. Mortality in rheumatoid arthritis: the impact of disease activity, treatment with glucocorticoids, TNFα inhibitors and rituximab. Ann Rheum Dis 2013, 10.1136/annrheumdis-2013-204021.
32. Prevoo M.L., van't Hof M.A., Kuper H.H., et al. Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 1995, 38:44-48.
33. Smolen J.S., Breedveld F.C., Schiff M.H., et al. A simplified disease activity index for rheumatoid arthritis for use in clinical practice. Rheumatol Oxf Engl 2003, 42:244-257.
34. Aletaha D., Nell V.P.K., Stamm T., et al. Acute phase reactants add little to composite disease activity indices for rheumatoid arthritis: validation of a clinical activity score. Arthritis Res Ther 2005, 7:R796-R806.
35. Gaujoux-Viala C., Mouterde G., Baillet A., et al. Evaluating disease activity in rheumatoid arthritis: which composite index is best? A systematic literature analysis of studies comparing the psychometric properties of the DAS, DAS28, SDAI and CDAI. Joint Bone Spine 2012, 79:149-155.
36. Sheehy C., Evans V., Hasthorpe H., et al. Revising DAS28 scores for remission in rheumatoid arthritis. Clin Rheumatol 2014, 33:269-272.
37. Gaujoux-Viala C. C-reactive protein versus erythrocyte sedimentation rate in estimating the 28-joint disease activity score. J Rheumatol 2013, 40:1785-1787.
38. Felson D.T., Smolen J.S., Wells G., et al. American College of Rheumatology/European League against Rheumatism provisional definition of remission in rheumatoid arthritis for clinical trials. Ann Rheum Dis 2011, 70:404-413.
39. Studenic P., Smolen J.S., Aletaha D. Near misses of ACR/EULAR criteria for remission: effects of patient global assessment in Boolean and index-based definitions. Ann Rheum Dis 2012, 71:1702-1705.
40. Knevel R., Schoels M., Huizinga T.W.J., et al. Current evidence for a strategic approach to the management of rheumatoid arthritis with disease-modifying antirheumatic drugs: a systematic literature review informing the EULAR recommendations for the management of rheumatoid arthritis. Ann Rheum Dis 2010, 69:987-994.
41. Haraoui B., Smolen J.S., Aletaha D., et al. Treating rheumatoid arthritis to target: multinational recommendations assessment questionnaire. Ann Rheum Dis 2011, 70:1999-2002.
42. Schipper L.G., van Hulst L.T., Grol R., et al. Meta-analysis of tight control strategies in rheumatoid arthritis: protocolized treatment has additional value with respect to the clinical outcome. Rheumatology (Oxford) 2010, 49:2154-2164.
43. Escalas C., Dalichampt M., Combe B., et al. Effect of adherence to European treatment recommendations on early arthritis outcome: data from the ESPOIR cohort. Ann Rheum Dis 2012, 71:1803-1808.
44. Momohara S., Inoue E., Ikari K., et al. Decrease in orthopaedic operations, including total joint replacements, in patients with rheumatoid arthritis between 2001 and 2007: data from Japanese outpatients in a single institute-based large observational cohort (IORRA). Ann Rheum Dis 2010, 69:312-313.
45. Barnabe C., Martin B.-J., Ghali W.A. Systematic review and meta-analysis: anti-tumor necrosis factor α therapy and cardiovascular events in rheumatoid arthritis. Arthritis Care Res 2011, 63:522-529.
46. Combe B., Landewe R., Lukas C., et al. EULAR recommendations for the management of early arthritis: report of a task force of the European Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis 2007, 66:34-45.
47. Saag K.G., Teng G.G., Patkar N.M., et al. American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis. Arthritis Rheum 2008, 59:762-784.
48. Smolen J.S., Landewé R., Breedveld F.C., et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs. Ann Rheum Dis 2010, 69:964-975.
49. Singh J.A., Furst D.E., Bharat A., et al. 2012 update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis. Arthritis Care Res 2012, 64:625-639.
50. Gaujoux-Viala C., Paternotte S., Combe B., et al. Evidence of the symptomatic and structural efficacy of methotrexate in daily practice as the first disease-modifying drug in rheumatoid arthritis despite its suboptimal use: results from the ESPOIR early synovitis cohort. Rheumatol Oxf Engl 2012, 51:1648-1654.
51. Visser K., van der Heijde D. Optimal dosage and route of administration of methotrexate in rheumatoid arthritis: a systematic review of the literature. Ann Rheum Dis 2009, 68:1094-1099.
52. Katchamart W., Trudeau J., Phumethum V., et al. Efficacy and toxicity of methotrexate (MTX) monotherapy versus MTX combination therapy with non-biological disease-modifying antirheumatic drugs in rheumatoid arthritis: a systematic review and meta-analysis. Ann Rheum Dis 2009, 68:1105-1112.
53. De Jong P.H., Hazes J.M., Barendregt P.J., et al. Induction therapy with a combination of DMARDs is better than methotrexate monotherapy: first results of the tREACH trial. Ann Rheum Dis 2013, 72:72-78.
54. Moreland L.W., O'Dell J.R., Paulus H.E., et al. A randomized comparative effectiveness study of oral triple therapy versus etanercept plus methotrexate in early, aggressive rheumatoid arthritis. Arthritis Rheum 2012, 64:2824-2835.
55. De Cock D., Meyfroidt S., Joly J., et al. For remission induction with glucocorticoid bridging, methotrexate monotherapy is as effective as a combination with other DMARDs, with fewer reported side effects: 4-month primary outcome of CareRA, a randomized induction strategy and treat-to-target trial in early RA. Arthritis Rheum 2013, 14. [Late Breaking Abstract 14].
56. Pedro S., Wolfe F., Jalal H., et al. Arthritis Rheum 2013, 65:S450. [Abstract 1055].
57. Gaujoux-Viala C., Smolen J.S., Landewé R., et al. Current evidence for the management of rheumatoid arthritis with synthetic disease-modifying antirheumatic drugs: a systematic literature review informing the EULAR recommendations for the management of rheumatoid arthritis. Ann Rheum Dis 2010, 69:1004-1009.
58. Pullar T., Hunter J.A., Capell H.A. Sulphasalazine in the treatment of rheumatoid arthritis: relationship of dose and serum levels to efficacy. Br J Rheumatol 1985, 24:269-276.
59. Capell H.A. Clinical efficacy of sulphasalazine: a review. Br J Rheumatol 1995, 34:35-39.
60. Caplan L., Wolfe F., Russell A.S., et al. Corticosteroid use in rheumatoid arthritis: prevalence, predictors, correlates, and outcomes. J Rheumatol 2007, 34:696-705.
61. Kirwan J.R. The effect of glucocorticoids on joint destruction in rheumatoid arthritis. The Arthritis and Rheumatism Council Low-Dose Glucocorticoid Study Group [see comments]. N Engl J Med 1995, 333:142-146.
62. Van Everdingen A.A., Jacobs J.W.G., Siewertsz Van Reesema D.R., et al. Low-dose prednisone therapy for patients with early active rheumatoid arthritis: clinical efficacy, disease-modifying properties, and side effects: a randomized, double-blind, placebo-controlled clinical trial. Ann Intern Med 2002, 136:1-12.
63. Wassenberg S., Rau R., Steinfeld P., et al. Very low-dose prednisolone in early rheumatoid arthritis retards radiographic progression over two years: a multicenter, double-blind, placebo-controlled trial. Arthritis Rheum 2005, 52:3371-3380.
64. Svensson B., Boonen A., Albertsson K., et al. Low-dose prednisolone in addition to the initial disease-modifying antirheumatic drug in patients with early active rheumatoid arthritis reduces joint destruction and increases the remission rate: a two-year randomized trial. Arthritis Rheum 2005, 52:3360-3370.
65. Kirwan J., Bijlsma J., Boers M. Effects of glucocorticoids on radiological progression in rheumatoid arthritis. Cochrane Database Syst Rev 2007, 1:CD00635610. [n.d.].
66. Bakker M.F., Jacobs J.W.G., Welsing P.M.J., et al. Low-dose prednisone inclusion in a methotrexate-based, tight control strategy for early rheumatoid arthritis: a randomized trial. Ann Intern Med 2012, 156:329-339.
67. Hoes J.N., Jacobs J.W.G., Verstappen S.M.M., et al. Adverse events of low- to medium-dose oral glucocorticoids in inflammatory diseases: a meta-analysis. Ann Rheum Dis 2009, 68:1833-1838.
68. Dixon W.G., Abrahamowicz M., Beauchamp M.-E., et al. Immediate and delayed impact of oral glucocorticoid therapy on risk of serious infection in older patients with rheumatoid arthritis: a nested case-control analysis. Ann Rheum Dis 2012, 71:1128-1133.
69. Del Rincón I., Battafarano D.F., Restrepo J.F., et al. Glucocorticoid dose thresholds associated with all-cause and cardiovascular mortality in rheumatoid arthritis. Arthritis Rheum 2014, 66:264-272.
70. Van der Goes M.C., Jacobs J.W.G., Jurgens M.S., et al. Are changes in bone mineral density different between groups of early rheumatoid arthritis patients treated according to a tight control strategy with or without prednisone if osteoporosis prophylaxis is applied?. Osteoporos Int 2013, 24:1429-1436.
71. Hetland M.L., Østergaard M., Ejbjerg B., et al. Short- and long-term efficacy of intra-articular injections with betamethasone as part of a treat-to-target strategy in early rheumatoid arthritis: impact of joint area, repeated injections, MRI findings, anti-CCP, IgM-RF and CRP. Ann Rheum Dis 2012, 71:851-856.
72. Vastesaeger N., Xu S., Aletaha D., et al. A pilot risk model for the prediction of rapid radiographic progression in rheumatoid arthritis. Rheumatology (Oxford) 2009, 48:1114-1121.
73. Visser K., Goekoop-Ruiterman Y.P., de Vries-Bouwstra J.K., et al. A matrix risk model for the prediction of rapid radiographic progression in patients with rheumatoid arthritis receiving different dynamic treatment strategies: post hoc analyses from the BeSt study. Ann Rheum Dis 2010, 69:1333-1337.
74. Saevarsdottir S., Wallin H., Seddighzadeh M., et al. Predictors of response to methotrexate in early DMARD-naive rheumatoid arthritis: results from the initial open-label phase of the SWEFOT trial. Ann Rheum Dis 2011, 70:469-475.
75. Fautrel B., Granger B., Combe B., et al. Matrix to predict rapid radiographic progression of early rheumatoid arthritis patients from the community treated with methotrexate or leflunomide: results from the ESPOIR cohort. Arthritis Res Ther 2012, 14:R249.
76. Klarenbeek N.B., Güler-Yüksel M., van der Kooij S.M., et al. The impact of four dynamic, goal-steered treatment strategies on the 5-year outcomes of rheumatoid arthritis patients in the BeSt study. Ann Rheum Dis 2011, 70:1039-1046.
77. Nam J.L., Winthrop K.L., van Vollenhoven R.F., et al. Current evidence for the management of rheumatoid arthritis with biological disease-modifying antirheumatic drugs: a systematic literature review informing the EULAR recommendations for the management of RA. Ann Rheum Dis 2010, 69:976-986.
78. Singh J.A., Christensen R., Wells G.A., et al. A network meta-analysis of randomized controlled trials of biologics for rheumatoid arthritis: a Cochrane overview. CMAJ 2009, 181:787-796.
79. Schiff M., Weinblatt M.E., Valente R., et al. Head-to-head comparison of subcutaneous abatacept versus adalimumab for rheumatoid arthritis: two-year efficacy and safety findings from AMPLE trial. Ann Rheum Dis 2014, 73:86-94.
80. Singh J.A., Christensen R., Wells G.A., et al. Biologics for rheumatoid arthritis: an overview of Cochrane reviews. Cochrane Database Syst Rev 2009, 4:CD007848.
81. Burmester G.-R., Kivitz A.J., Kupper H., et al. Efficacy and safety of ascending methotrexate dose in combination with adalimumab: the randomised CONCERTO trial. Ann Rheum Dis 2014, [Epub ahead of print]. 10.1136/annrheumdis-2013-204769.
82. Krieckaert C.L., Nurmohamed M.T., Wolbink G.J. Methotrexate reduces immunogenicity in adalimumab treated rheumatoid arthritis patients in a dose dependent manner. Ann Rheum Dis 2012, 71:1914-1915.
83. Manders S., Kievit W., Brus H., et al. Mode of action change not necessary after failing the first tumor necrosis factor inhibitor: preliminary results of a randomized controlled trial. Arthritis Rheum 2013, 65:S600.
84. Nishimoto N., Hashimoto J., Miyasaka N., et al. Study of active controlled monotherapy used for rheumatoid arthritis, an IL-6 inhibitor (SAMURAI): evidence of clinical and radiographic benefit from an x ray reader-blinded randomised controlled trial of tocilizumab. Ann Rheum Dis 2007, 66:1162-1167.
85. Jones G., Sebba A., Gu J., et al. Comparison of tocilizumab monotherapy versus methotrexate monotherapy in patients with moderate to severe rheumatoid arthritis: the AMBITION study. Ann Rheum Dis 2010, 69:88-96.
86. Burmester G., Rigby W., van Vollenhoven R., et al. Tocilizumab (TCZ) in combination and monotherapy versus methotrexate (MTX) in MTX-naive patients with early rheumatoid arthritis (RA): clinical and radiographic outcomes from a randomised, placebo-controlled trial. Ann Rheum Dis 2013, 72:63.
87. Gabay C., Emery P., van Vollenhoven R., et al. Tocilizumab monotherapy versus adalimumab monotherapy for treatment of rheumatoid arthritis (ADACTA): a randomised, double-blind, controlled phase 4 trial. Lancet 2013, 381:1541-1550.
88. Dougados M., Kissel K., Conaghan P.G., et al. Clinical, radiographic and immunogenic effects after 1 year of tocilizumab-based treatment strategies in rheumatoid arthritis: the ACT-RAY study. Ann Rheum Dis 2014, 73:803-809.
89. Burmester G.R., Mariette X., Montecucco C., et al. Adalimumab alone and in combination with disease-modifying antirheumatic drugs for the treatment of rheumatoid arthritis in clinical practice: the Research in Active Rheumatoid Arthritis (ReAct) trial. Ann Rheum Dis 2007, 66:732-739.
90. Strangfeld A., Hierse F., Kekow J., et al. Comparative effectiveness of tumour necrosis factor alpha inhibitors in combination with either methotrexate or leflunomide. Ann Rheum Dis 2009, 68:1856-1862.
91. Salliot C., Finckh A., Katchamart W., et al. Indirect comparisons of the efficacy of biological antirheumatic agents in rheumatoid arthritis in patients with an inadequate response to conventional disease-modifying antirheumatic drugs or to an anti-tumour necrosis factor agent: a meta-analysis. Ann Rheum Dis 2011, 70:266-271.
92. Gottenberg J., Brocq O., Perdriger A., et al. Therapeutic strategy in patients with rheumatoid arthritis and insufficient response to a 1st anti-TNF: results of the multicenter randomized controlled "ROC" trial. Arthritis Rheum 2013, 65:S624.
93. Du Pan S.M., Scherer A., Gabay C., et al. Differential drug retention between anti-TNF agents and alternative biological agents after inadequate response to an anti-TNF agent in rheumatoid arthritis patients. Ann Rheum Dis 2012, 71:997-999.
94. Kekow J., Mueller-Ladner U., Schulze-Koops H. Rituximab is more effective than second anti-TNF therapy in rheumatoid arthritis patients and previous TNFα blocker failure. Biol Targets Ther 2012, 6:191-199.
95. Mulleman D., Ducourau E., Paintaud G., et al. Should anti-TNF-α drug levels and/or anti-drug antibodies be assayed in patients treated for rheumatoid arthritis?. Joint Bone Spine 2012, 79:109-112.
96. Tanaka Y., Takeuchi T., Mimori T., et al. Discontinuation of infliximab after attaining low disease activity in patients with rheumatoid arthritis: RRR (remission induction by Remicade in RA) study. Ann Rheum Dis 2010, 69:1286-1291.
97. Smolen J.S., Emery P., Ferraccioli G.F., et al. Certolizumab-pegol in rheumatoid arthritis patients with low to moderate activity: the CERTAIN double-blind, randomised, placebo-controlled trial. Ann Rheum Dis 2014, [Epub ahead of print]. 10.1136/annrheumdis-2013-204632.
98. Chatzidionysiou K., Turesson C., Teleman A. A multicenter, randomized, controlled, open-label pilot study of the feasibility of discontinuation of adalimumab in rheumatoid arthritis patients in stable clinical remission. Arthritis Rheum 2012, 64:S336.
99. Smolen J.S., Nash P., Durez P., et al. Maintenance, reduction, or withdrawal of etanercept after treatment with etanercept and methotrexate in patients with moderate rheumatoid arthritis (PRESERVE): a randomised controlled trial. Lancet 2013, 381:918-929.
100. Fautrel B., Gandjbakhch F., Foltz V., et al. Targeting the lowest efficacious dose for rheumatoid arthritis patients in remission: clinical and structural impact of a stepdown strategy trial based on progressive spacing of TNF-blocker injections (STRASS trial). Ann Rheum Dis 2013, 72:72.
101. Smolen J.S., Emery P., Fleischmann R., et al. Adjustment of therapy in rheumatoid arthritis on the basis of achievement of stable low disease activity with adalimumab plus methotrexate or methotrexate alone: the randomised controlled OPTIMA trial. Lancet 2014, 383:321-332.
102. Emery P., Hammoudeh M., Fitzgerald O. Assessing maintenance of remission with reduced dose etanercept plus methotrexate, methotrexate alone, or placebo in patients with early rheumatoid arthritis who achieved remission with etanercept and methotrextate: the PRIZE study. Ann Rheum Dis 2013, 3:399.
103. Klarenbeek N.B., van der Kooij S.M., Guler-Yuksel M., et al. Discontinuing treatment in patients with rheumatoid arthritis in sustained clinical remission: exploratory analyses from the BeSt study. Ann Rheum Dis 2011, 70:315-319.
104. Takeuchi T., Matsubara T., Ohta S. Abatacept biologic-free remission study in established rheumatoid arthritis: ORION study. Ann Rheum Dis 2013, 3:613.
105. Nampei A., Nagayama Y. Discontinuation of tocilizumab after attaining remission in patients with rheumatoid arthritis. Ann Rheum Dis 2013, 3:877.
106. Batticciotto A., Varisco V., Antivalle M. Dose reduction in patients with rheumatoid arthritis responding to the standard rituximab regimen. Ann Rheum Dis 2013, 3:877.
107. Brocq O., Millasseau E., Albert C., et al. Effect of discontinuing TNF-alpha antagonist therapy in patients with remission of rheumatoid arthritis. Joint Bone Spine 2009, 76:350-355.
108. Cohen G., Gossec L., Dougados M., et al. Radiological damage in patients with rheumatoid arthritis on sustained remission. Ann Rheum Dis 2007, 66:358-363.
109. Lillegraven S., Prince F.H.M., Shadick N.A., et al. Remission and radiographic outcome in rheumatoid arthritis: application of the 2011 ACR/EULAR remission criteria in an observational cohort. Ann Rheum Dis 2012, 71:681-686.
110. Molenaar E.T., Voskuyl A.E., Dinant H.J., et al. Progression of radiologic damage in patients with rheumatoid arthritis in clinical remission. Arthritis Rheum 2004, 50:36-42.
111. Tishler M., Caspi D., Yaron M. Methotrexate treatment of rheumatoid arthritis: is a fortnightly maintenance schedule enough?. Ann Rheum Dis 1992, 51:1330-1331.
112. Luis M., Pacheco-Tena C., Cazarín-Barrientos J., et al. Comparison of two schedules for administering oral low-dose methotrexate (weekly versus every-other-week) in patients with rheumatoid arthritis in remission: a twenty-four week, single-blind, randomized study. Arthritis Rheum 1999, 42:2160-2165.
113. Kremer J.M., Rynes R.I., Bartholomew L.E. Severe flare of rheumatoid arthritis after discontinuation of long-term methotrexate therapy. Double-blind study. Am J Med 1987, 82:781-786.
114. Ten Wolde S., Breedveld F.C., Hermans J., et al. Randomised placebo-controlled study of stopping second-line drugs in rheumatoid arthritis. Lancet 1996, 347:347-352.
115. O'Mahony R., Richards A., Deighton C., et al. Withdrawal of disease-modifying antirheumatic drugs in patients with rheumatoid arthritis: a systematic review and meta-analysis. Ann Rheum Dis 2010, 69:1823-1826.
116. Ten Wolde S., Hermans J., Breedveld F.C., et al. Effect of resumption of second-line drugs in patients with rheumatoid arthritis that flared up after treatment discontinuation. Ann Rheum Dis 1997, 56:235-239.
117. Baecklund E., Iliadou A., Askling J., et al. Association of chronic inflammation, not its treatment, with increased lymphoma risk in rheumatoid arthritis. Arthritis Rheum 2006, 54:692-701.
118. Gonzalez-Gay M.A., Gonzalez-Juanatey C., Piñeiro A., et al. High-grade C-reactive protein elevation correlates with accelerated atherogenesis in patients with rheumatoid arthritis. J Rheumatol 2005, 32:1219-1223.
119. Choi H.K., Hernan M.A., Seeger J.D., et al. Methotrexate and mortality in patients with rheumatoid arthritis: a prospective study. Lancet 2002, 359:1173-1177.
120. Westlake S.L., Colebatch A.N., Baird J., et al. Tumour necrosis factor antagonists and the risk of cardiovascular disease in patients with rheumatoid arthritis: a systematic literature review. Rheumatology (Oxford) 2011, 50:518-531.
121. Al-Katma M.K., Bissada N.F., Bordeaux J.M., et al. Control of periodontal infection reduces the severity of active rheumatoid arthritis. J Clin Rheumatol 2007, 13:134-137.
122. Ortiz P., Bissada N.F., Palomo L., et al. Periodontal therapy reduces the severity of active rheumatoid arthritis in patients treated with or without tumor necrosis factor inhibitors. J Periodontol 2009, 80:535-540.